These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33350170)

  • 1. Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease.
    Assassi S; Li N; Volkmann ER; Mayes MD; Rünger D; Ying J; Roth MD; Hinchcliff M; Khanna D; Frech T; Clements PJ; Furst DE; Goldin J; Bernstein EJ; Castelino FV; Domsic RT; Gordon JK; Hant FN; Shah AA; Shanmugam VK; Steen VD; Elashoff RM; Tashkin DP
    Arthritis Rheumatol; 2021 Jun; 73(6):1005-1013. PubMed ID: 33350170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
    Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
    Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
    Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
    Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease.
    Assassi S; Volkmann ER; Zheng WJ; Wang X; Wilhalme H; Lyons MA; Roth MD; Tashkin DP
    Ann Rheum Dis; 2022 Jun; 81(6):854-860. PubMed ID: 35190386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
    Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
    Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
    Tashkin DP; Volkmann ER; Tseng CH; Roth MD; Khanna D; Furst DE; Clements PJ; Theodore A; Kafaja S; Kim GH; Goldin J; Ariolla E; Elashoff RM
    Chest; 2017 Apr; 151(4):813-820. PubMed ID: 28012804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
    Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
    Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
    Ma X; Tang R; Luo M; Zeng Z; Shi Y; Tang B; Xiao R
    Clin Rheumatol; 2021 Aug; 40(8):3185-3193. PubMed ID: 34080081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
    Zheng JN; Yang QR; Zhu GQ; Pan L; Xia JX; Wang Q
    Mod Rheumatol; 2020 Jul; 30(4):687-695. PubMed ID: 31269839
    [No Abstract]   [Full Text] [Related]  

  • 14. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Yilmaz N; Can M; Kocakaya D; Karakurt S; Yavuz S
    Int J Rheum Dis; 2014 Nov; 17(8):923-8. PubMed ID: 24864029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.
    Kim GHJ; Tashkin DP; Lo P; Brown MS; Volkmann ER; Gjertson DW; Khanna D; Elashoff RM; Tseng CH; Roth MD; Goldin JG
    Arthritis Rheumatol; 2020 Feb; 72(2):316-325. PubMed ID: 31430058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
    Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
    Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
    Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
    J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.
    Volkmann ER; Tashkin DP; Roth MD; Li N; Charles J; Mayes M; Kim G; Goldin J; Pourzand L; Clements PJ; Furst DE; Khanna D; Elashoff RM; Assassi S
    Semin Arthritis Rheum; 2020 Oct; 50(5):963-967. PubMed ID: 32906032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
    Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
    Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.